Per Hellman
Overview
Explore the profile of Per Hellman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
3271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klimacek B, Akerstrom T, Anneback M, Hellman P, Norlen O, Stalberg P
Langenbecks Arch Surg
. 2025 Mar;
410(1):90.
PMID: 40047926
Purpose: Small intestinal neuroendocrine tumours (SI-NETs) are the most common malignancy of the small bowel. Curative treatment is surgical, with exploratory laparotomy considered the standard approach. This study aimed to...
2.
Gillett D, Senanayake R, MacFarlane J, Bashari W, Palma A, Hu L, et al.
J Nucl Med
. 2025 Jan;
66(3):434-440.
PMID: 39884776
Primary aldosteronism (PA) is a common, potentially reversible, cause of hypertension. Distinguishing unilateral from bilateral PA is critical when deciding who should be offered surgery (unilateral adrenalectomy). Recent studies have...
3.
Backman S, Botling J, Nord H, Ghosal S, Stalberg P, Juhlin C, et al.
J Pathol
. 2024 Oct;
264(4):357-370.
PMID: 39360347
Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular may progress from a low/intermediate to a high-grade...
4.
Silins I, Moreno A, Wall A, Aigbirhio F, Gurnell M, Brown M, et al.
EJNMMI Res
. 2024 May;
14(1):48.
PMID: 38771379
Background: [C]metomidate, a methyl ester analogue of etomidate, is used for positron emission tomography of adrenocortical cancer, and has been tested in recent clinical trials for lateralization in primary aldosteronism...
5.
Backman S, Botling J, Nord H, Ghosal S, Stalberg P, Juhlin C, et al.
medRxiv
. 2024 Feb;
PMID: 38313278
Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular, show frequent progression from a low/intermediate to a...
6.
Vyakaranam A, Mahamed M, Hellman P, Eriksson O, Espes D, Christoffersson G, et al.
Diabetologia
. 2023 Nov;
67(1):199-208.
PMID: 37935826
Aims/hypothesis: Compromised pancreatic sympathetic innervation has been suggested as a factor involved in both immune-mediated beta cell destruction and endocrine dysregulation of pancreatic islets. To further explore these intriguing findings,...
7.
Edfeldt K, Hellman P, Granberg D, Lagergren P, Thiis-Evensen E, Sundin A, et al.
J Neuroendocrinol
. 2023 Oct;
35(10):e13342.
PMID: 37807573
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health-related quality of life (HRQoL)....
8.
Kjaer J, Clancy T, Thornell A, Andersson N, Hellman P, Crona J, et al.
Ann Surg Open
. 2023 Aug;
3(1):e151.
PMID: 37600107
Objective: To determine the association of primary tumor resection in stage IV pancreatic neuroendocrine tumors (Pan-NET) and survival in a propensity-score matched study. Background: Pan-NET are often diagnosed with stage...
9.
Kjaer J, Norlen O, Hellman P, Stalberg P
World J Surg
. 2023 Feb;
47(4):1086.
PMID: 36757425
No abstract available.
10.
Kjaer J, Norlen O, Hellman P, Stalberg P
World J Surg
. 2023 Jan;
47(4):1084-1085.
PMID: 36705741
No abstract available.